➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Harvard Business School
Baxter
McKinsey
Merck
Johnson and Johnson
McKesson

Last Updated: May 11, 2021

DrugPatentWatch Database Preview

PROLIA Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Summary for Tradename: PROLIA
Recent Clinical Trials for PROLIA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Columbia UniversityPhase 2
Kunming Pharmaceuticals, Inc.Phase 1
Australian and New Zealand Intensive Care Research CentrePhase 2

See all PROLIA clinical trials

Pharmacology for PROLIA
Mechanism of ActionRANK Ligand Blocking Activity

Company Disclosures: US Patents for PROLIA

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Get Started for $10 Immunex Corporation (Seattle, WA) 2016-12-23 RX Orphan company
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Get Started for $10 Amgen Inc. (Thousand Oaks, CA) 2017-04-16 RX Orphan company
Amgen PROLIA denosumab INJECTABLE; SUBCUTANEOUS 125320 001 2010-06-01   Get Started for $10 Amgen Inc. (Thousand Oaks, CA) Amgen Fremont Inc. (Fremont, CA) 2021-06-26 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for PROLIA

These patents were identified by searching patent claims

Supplementary Protection Certificates for PROLIA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
132010901893988 Italy   Get Started for $10 PRODUCT NAME: DENOSUMAB(PROLIA); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/10/618/001-004, 20100526
300465 Netherlands   Get Started for $10 PRODUCT NAME: DENOSUMAB; REGISTRATION NO/DATE: EU/1/10/618/001-004 20100526
91757 Luxembourg   Get Started for $10 PRODUCT NAME: DENOSUMAB ET SES DERIVES PHARMACEUTIQUEMENT ACCEPTABLES (PROLIA ); AUTHORISATION NUMBER AND DATE: EU/1/10/618/001-004 20100528
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Colorcon
Dow
McKinsey
Mallinckrodt
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.